Skip to Main Content

Paper Details

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Clin Cancer Res
56
2015

Datasets

Release 1.2